Breaking News Instant updates and real-time market news.

STML

Stemline

$14.25

0.245 (1.75%)

07:17
04/25/19
04/25
07:17
04/25/19
07:17

Stemline announces Elzonris data published

Stemline announced that the pivotal trial results of Elzonris, a targeted therapy directed to CD123, in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, have been published in the latest issue of the New England Journal of Medicine. Elzonris is approved by the FDA for the treatment of BPDCN in adults and pediatric patients two years and older, and is commercially available in the U.S.

  • 31

    May

STML Stemline
$14.25

0.245 (1.75%)

02/06/19
PIPR
02/06/19
NO CHANGE
Target $23
PIPR
Overweight
Stemline price target lowered to $23 from $30 at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro lowered his price target for Stemline Therapeutics to $23 to reflect reduced 2019 Elzonris estimates. Given the shortened Q1 selling period and expectations that early use will be heavily weighted towards blastic plasmacytoid dendritic cell neoplasm, who receive fewer cycles of therapy, the analyst reduced his 2019 Elzonris estimates. However, he believes the drug's long-term opportunity is intact. Catanzaro continues to view Stemline shares as undervalued and thinks the now approved U.S. BPDCN label is a $250M opportunity. He keeps an Overweight rating on Stemline Therapeutics.
03/06/19
PIPR
03/06/19
NO CHANGE
PIPR
Departure of Gottlieb brings some biopharma uncertainty, says Piper Jaffray
Piper Jaffray remains "largely bullish" on the biopharma sector but acknowledges a "new and unexpected" source of uncertainty now with the announced departure of FDA commissioner Scott Gottlieb, analysts led by Christopher Raymond tell investors in a research note. With a track record of favoring innovation and pushing for increased regulatory efficiency while also advocating for more competition, Dr. Gottlieb was about as "market friendly, patient focused and industry friendly as one could have hoped," Piper writes. The firm adds that while it has no reason to believe the next commissioner "will be quite as radical and potentially damaging to the industry," it does think investors would do well to watch the selection process very closely.
03/11/19
PIPR
03/11/19
NO CHANGE
Target $23
PIPR
Overweight
Stemline's Elzonris to become BPDCN standard of care, says Piper Jaffray
After speaking with a key opinion leader, Piper Jaffray analyst Joseph Catanzaro says he continues to have no doubt that Stemline Therapeutics' Elzonris will become standard of care for blastic plasmacytoid dendritic cell neoplasm. The analyst remains "very comfortable" with his 500 patient annual U.S. incidence estimate. He models for $300M in peak U.S. sales for Elzonris and maintains an Overweight rating on Stemline with a $23 price target.
03/18/19
PIPR
03/18/19
NO CHANGE
Target $23
PIPR
Overweight
Stemline sees positive physician feedback in all categories, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating and $23 price target on Stemline, saying his conversations with the management after the company's Q4 results reflected "very positive" feedback from physicians with patient enrollments "in all major sales territories." The analyst believes that the company's Elzonris sales may reach $1.9M, and "expansion opportunities in subsets of CMML and MF" could take shape by mid-2019.

TODAY'S FREE FLY STORIES

12:10
06/25/19
06/25
12:10
06/25/19
12:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY fell…

AGN

Allergan

$164.20

34.55 (26.65%)

, ABBV

AbbVie

$66.78

-11.63 (-14.83%)

12:08
06/25/19
06/25
12:08
06/25/19
12:08
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have slid in…

AGN

Allergan

$164.20

34.55 (26.65%)

ABBV

AbbVie

$66.78

-11.63 (-14.83%)

TMUS

T-Mobile

$74.93

-0.61 (-0.81%)

S

Sprint

$6.86

(0.00%)

DISH

Dish

$37.93

-0.66 (-1.71%)

LEN

Lennar

$48.75

-2.66 (-5.17%)

PYX

Pyxus

$16.70

3.28 (24.44%)

GRUB

GrubHub

$75.31

3.26 (4.52%)

ALDX

Aldeyra

$5.85

-1.23 (-17.37%)

BHF

Brighthouse Financial

$32.74

-5.36 (-14.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 09

    Jul

  • 16

    Sep

DLTR

Dollar Tree

$109.86

-2.86 (-2.54%)

12:08
06/25/19
06/25
12:08
06/25/19
12:08
Hot Stocks
Dollar Tree director Thomas Saunders sells over $1.6M in company shares »

Dollar Tree director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$13.72

-0.2 (-1.44%)

12:05
06/25/19
06/25
12:05
06/25/19
12:05
Options
SSR Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDX

Aldeyra

$5.85

-1.23 (-17.37%)

12:02
06/25/19
06/25
12:02
06/25/19
12:02
Recommendations
Aldeyra analyst commentary at Stifel »

Stifel says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

UNH

UnitedHealth

$249.06

-0.59 (-0.24%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Periodicals
UnitedHealth buys PatientsLikeMe after scrutiny over Chinese investor, CNBC says »

According to a story out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

RGS

Regis

$16.62

-1.15 (-6.47%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Regis falls -6.4% »

Regis is down -6.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$14.36

-1.02 (-6.63%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
EQT Corporation falls -6.6% »

EQT Corporation is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

ABBV

AbbVie

$66.64

-11.77 (-15.01%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
AbbVie falls -15.1% »

AbbVie is down -15.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 16

    Sep

USNA

Usana

$78.92

6.515 (9.00%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Usana rises 8.6% »

Usana is up 8.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYX

Pyxus

$16.40

2.98 (22.21%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Pyxus rises 23.0% »

Pyxus is up 23.0%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$163.99

34.34 (26.49%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Allergan rises 26.6% »

Allergan is up 26.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACST

Acasti Pharma

$1.03

0.02 (1.98%)

, AMRN

Amarin

$18.55

0.12 (0.65%)

11:59
06/25/19
06/25
11:59
06/25/19
11:59
Periodicals
Acasti Pharma mentioned positively by Seeking Alpha contributor »

Seeking Alpha contributor…

ACST

Acasti Pharma

$1.03

0.02 (1.98%)

AMRN

Amarin

$18.55

0.12 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Sep

AMAT

Applied Materials

$42.33

(0.00%)

11:55
06/25/19
06/25
11:55
06/25/19
11:55
Options
Applied Materials put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

ACER

Acer Therapeutics

$4.34

-14.83 (-77.36%)

11:52
06/25/19
06/25
11:52
06/25/19
11:52
Downgrade
Acer Therapeutics rating change at Raymond James »

Acer Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

KNX

Knight-Swift

$30.43

0.37 (1.23%)

11:45
06/25/19
06/25
11:45
06/25/19
11:45
Options
Knight Transportation call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

11:45
06/25/19
06/25
11:45
06/25/19
11:45
General news
Breaking General news story  »

Atlanta Federal Reserve…

AMZN

Amazon.com

$1,890.97

-22.46 (-1.17%)

, MSFT

Microsoft

$134.89

-2.91 (-2.11%)

11:44
06/25/19
06/25
11:44
06/25/19
11:44
On The Fly
Microsoft slips as analyst sees stock 'materially overvalued' as Azure 'not AWS' »

Saying that Microsoft…

AMZN

Amazon.com

$1,890.97

-22.46 (-1.17%)

MSFT

Microsoft

$134.89

-2.91 (-2.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 09

    Jul

  • 10

    Jul

  • 06

    Aug

WPX

WPX Energy

$11.01

-0.02 (-0.18%)

11:35
06/25/19
06/25
11:35
06/25/19
11:35
Options
WPX Energy put volume heavy and directionally bearish »

Bearish flow noted in WPX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$51.10

-0.31 (-0.60%)

11:34
06/25/19
06/25
11:34
06/25/19
11:34
Hot Stocks
Lennar remains confident in reaching FY19 home delivery target of 50,000 homes »

Expects margins to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 28

    Jun

LEN

Lennar

$50.94

-0.47 (-0.91%)

11:33
06/25/19
06/25
11:33
06/25/19
11:33
Earnings
Lennar sees Q3 EPS $1.25-$1.35, consensus $1.52 »

Sees Q3 new orders of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 28

    Jun

11:30
06/25/19
06/25
11:30
06/25/19
11:30
General news
Treasury announced a $75 B batch of auctions for Thursday »

Treasury announced a $75…

ACER

Acer Therapeutics

$4.31

-14.86 (-77.52%)

11:25
06/25/19
06/25
11:25
06/25/19
11:25
Downgrade
Acer Therapeutics rating change  »

Acer Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

CLDR

Cloudera

$5.53

0.005 (0.09%)

11:25
06/25/19
06/25
11:25
06/25/19
11:25
Options
Cloudera call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CODI

Compass Diversified

$19.00

0.345 (1.85%)

11:25
06/25/19
06/25
11:25
06/25/19
11:25
Conference/Events
Compass Diversified to host investor & analyst meeting »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.